Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
Deutsche Initiates Coverage On Health Stocks As National Health Insurance Debate Rages On
In The Wake Of Failed Merger With Aetna, Humana Regains Outperform Rating From Oppenheimer
Zombie TrumpCare Is Back, But These Health Insurer Stocks Are Breaking Out (Investor's Business Daily)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Apr 2017Deutsche BankInitiates Coverage OnHold
Jan 2017Leerink SwannDowngradesOutperformMarket Perform
Jan 2017PiperJaffrayInitiates Coverage OnNeutral

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

View Comments and Join the Discussion!